Hanping Wang

2.8k total citations · 1 hit paper
129 papers, 1.5k citations indexed

About

Hanping Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Hanping Wang has authored 129 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 51 papers in Pulmonary and Respiratory Medicine and 24 papers in Molecular Biology. Recurrent topics in Hanping Wang's work include Cancer Immunotherapy and Biomarkers (45 papers), Lung Cancer Treatments and Mutations (35 papers) and Lung Cancer Research Studies (21 papers). Hanping Wang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (45 papers), Lung Cancer Treatments and Mutations (35 papers) and Lung Cancer Research Studies (21 papers). Hanping Wang collaborates with scholars based in China, United States and Germany. Hanping Wang's co-authors include Xiaoyan Si, Li Zhang, Xiaotong Zhang, Mengzhao Wang, Hong Yao, Lian Duan, Xiaoxiao Guo, Jiaxin Zhou, Nour Eissa and Peng Song and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Hanping Wang

120 papers receiving 1.5k citations

Hit Papers

Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor... 2024 2026 2025 2024 10 20 30 40
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma
    2024 43 citations Hanping Wang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hanping Wang China 21 586 445 337 205 146 129 1.5k
Shuo Ma United States 28 762 1.3× 213 0.5× 1.2k 3.6× 733 3.6× 134 0.9× 160 3.2k
Jiang Wang China 25 658 1.1× 172 0.4× 796 2.4× 630 3.1× 152 1.0× 97 2.4k
Masahiro Ito Japan 25 496 0.8× 451 1.0× 639 1.9× 122 0.6× 83 0.6× 126 2.1k
Jian Lei China 16 337 0.6× 343 0.8× 682 2.0× 106 0.5× 69 0.5× 64 1.5k
Wenfeng Li China 26 538 0.9× 380 0.9× 957 2.8× 319 1.6× 41 0.3× 111 2.2k
Xiaoyan Jiang Canada 36 709 1.2× 112 0.3× 1.7k 4.9× 782 3.8× 273 1.9× 151 4.4k
Xiaozheng Xu China 15 508 0.9× 218 0.5× 1.2k 3.5× 786 3.8× 111 0.8× 24 1.9k
Ning Yu China 25 346 0.6× 314 0.7× 667 2.0× 257 1.3× 71 0.5× 89 1.9k
Lie Wang China 33 716 1.2× 249 0.6× 1.7k 5.1× 1.1k 5.4× 157 1.1× 130 3.3k

Countries citing papers authored by Hanping Wang

Since Specialization
Citations

This map shows the geographic impact of Hanping Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hanping Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hanping Wang more than expected).

Fields of papers citing papers by Hanping Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hanping Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hanping Wang. The network helps show where Hanping Wang may publish in the future.

Co-authorship network of co-authors of Hanping Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Hanping Wang. A scholar is included among the top collaborators of Hanping Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hanping Wang. Hanping Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Li, Rui Meng, Jing Zhang, et al.. (2025). Safety and Efficacy of the First Subcutaneous ICI, Envafolimab, in the Treatment of Advanced Lung Cancer Patients: A Real‐World Study. Thoracic Cancer. 16(12). e70101–e70101.
2.
3.
4.
Si, Xiaoyan, Shafei Wu, Ruie Feng, et al.. (2024). Clinicopathological Characteristics of Inflammatory Myofibroblastic Tumor: A Single Center Retrospective Cohort Study. Thoracic Cancer. 16(1). e15496–e15496. 1 indexed citations
5.
6.
Miao, Kang, Xiaotong Zhang, Hanping Wang, Xiaoyan Si, & Li Zhang. (2023). Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer. Thoracic Cancer. 14(13). 1162–1170. 4 indexed citations
7.
Pan, Ruili, Minjiang Chen, Jing Zhao, et al.. (2022). Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis. Thoracic Cancer. 13(7). 1059–1066. 4 indexed citations
8.
Ni, Jun, Xiaoyan Si, Hanping Wang, Xiaotong Zhang, & Li Zhang. (2022). Prognostic biomarkers and immune cell infiltration characteristics in small cell lung cancer. SHILAP Revista de lepidopterología. 1(1). 18–24. 3 indexed citations
9.
Ni, Jun, Xiaotong Zhang, Hanping Wang, et al.. (2021). Clinical characteristics and prognostic model for extensive‐stage small cell lung cancer: A retrospective study over an 8‐year period. Thoracic Cancer. 13(4). 539–548. 9 indexed citations
10.
Wang, Hanping, Jiaxin Zhou, Xiaoxiao Guo, et al.. (2020). Use of glucocorticoids in the management of immunotherapy‐related adverse effects. Thoracic Cancer. 11(10). 3047–3052. 17 indexed citations
11.
Si, Xiaoyan, Jinwan Wang, Ying Cheng, et al.. (2020). A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 12. 3863580889–3863580889. 11 indexed citations
12.
Song, Peng, Hanping Wang, Xiaoxia Cui, et al.. (2020). Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non‐small cell lung cancer patients. Thoracic Cancer. 11(6). 1647–1654. 19 indexed citations
13.
Si, Xiaoyan, Ruili Pan, Shaohua Ma, et al.. (2020). Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer. Thoracic Cancer. 12(3). 357–363. 18 indexed citations
14.
Si, Xiaoyan, Hanping Wang, Xiaotong Zhang, et al.. (2020). Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum‐pemetrexed: The first report of two cases. Thoracic Cancer. 11(8). 2339–2342. 3 indexed citations
15.
Song, Peng, Hanping Wang, Xiaoxia Cui, et al.. (2020). Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients. Thoracic Cancer. 11(6). 1621–1632. 66 indexed citations
16.
Liu, Tao, Xiaotong Zhang, Xiaoyan Si, et al.. (2020). Opportunistic infections complicating immunotherapy for non‐small cell lung cancer. Thoracic Cancer. 11(6). 1689–1694. 15 indexed citations
17.
Duan, Lian, Linjie Wang, Hanping Wang, et al.. (2020). Clinical diagnosis and treatment of immune checkpoint inhibitors‐related endocrine dysfunction. Thoracic Cancer. 11(4). 1099–1104. 6 indexed citations
18.
Zhuang, Junling, Jianhua Du, Xiaoxiao Guo, et al.. (2020). Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events. Thoracic Cancer. 11(3). 799–804. 29 indexed citations
19.
Si, Xiaoyan, Chun‐Xia He, Li Zhang, et al.. (2019). Management of immune checkpoint inhibitor‐related dermatologic adverse events. Thoracic Cancer. 11(2). 488–492. 19 indexed citations
20.
Wang, Hanping, Li Zhang, Fenlai Tan, et al.. (2011). Phase I trial of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in Chinese patients with non-small cell lung cancer.. PubMed. 124(13). 1933–1933. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shuo Ma Breakdown of academic impact, for papers by Jiang Wang Breakdown of academic impact, for papers by Masahiro Ito Breakdown of academic impact, for papers by Jian Lei Breakdown of academic impact, for papers by Wenfeng Li Breakdown of academic impact, for papers by Xiaoyan Jiang Breakdown of academic impact, for papers by Xiaozheng Xu Breakdown of academic impact, for papers by Ning Yu Breakdown of academic impact, for papers by Lie Wang
Rankless by CCL
2026